Key insights
- Goldman Sachs maintained a Neutral rating on Rocket Lab USA (RKLB) despite strong revenue growth and a record backlog, citing delays in the Neutron rocket launch to Q1 2026. While RKLB beat revenue expectations, adjusted EBITDA fell short. Other analysts raised price targets, highlighting revenue growth and backlog strength. The Neutron launch delay introduces uncertainty, making its impact on the broader market minimal at this time.
Investing.com - Goldman Sachs has reiterated its Neutral rating and $47.00 price target on Rocket Lab USA (NASDAQ:RKLB) following the company’s third-quarter 2025 financial results. Currently trading at $49.97, RKLB has surged 165% over the past year despite recent pullbacks, according to InvestingPro data.
The space launch provider reported revenue and earnings per share that exceeded consensus expectations for the quarter, though adjusted EBITDA fell short of analyst forecasts. RKLB posted $554.53 million in revenue over the last twelve months, representing impressive 52.42% growth.
Rocket Lab announced a delay in the inaugural launch of its Neutron rocket to the first quarter of 2026, with plans to conduct three additional full-price launches within 12 months of the initial launch.
Despite a sequential decline in Electron launches during the quarter, the company reported accelerating demand with a record backlog of 49 launches, indicating strong future revenue potential.
The company’s Space Systems division demonstrated continued momentum, maintaining its backlog while delivering strong growth, though Goldman Sachs noted that risks associated with the upcoming Neutron launch remain difficult to evaluate.
In other recent news, Rocket Lab USA has reported significant developments in its financial performance and business strategy. The company posted third-quarter revenue of $155.1 million, which marks a 48% increase year-over-year and surpasses the consensus estimate of $151.9 million. However, Rocket Lab also reported an adjusted EBITDA loss of $26.3 million, which was greater than the anticipated $22.0 million loss. Analysts have responded to these results with various adjustments to their price targets and ratings. Needham raised its price target to $63, citing strong revenue growth and improved gross margins. Roth/MKM and KeyBanc both increased their price targets to $75, highlighting the company’s margin strength and growing backlog. Cantor Fitzgerald also increased its price target to $72, emphasizing the potential impact of Rocket Lab’s upcoming Neutron launch vehicle. Meanwhile, Citizens maintained a Market Perform rating, reflecting the mixed nature of the quarterly results. These developments indicate a cautious optimism among analysts regarding Rocket Lab’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.